Theramex

Explore the latest insights on Theramex and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Theramex’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Shionogi to Acquire IntraBio for $2.0B – Rare Neurodegenerative Disease Platform Anchored by FDA‑Approved AQNEURSA Expands Global Portfolio
CompanyDeals

Shionogi to Acquire IntraBio for $2.0B – Rare Neurodegenerative Disease Platform Anchored by FDA‑Approved AQNEURSA Expands Global Portfolio

Shionogi & Co., Ltd. (TYO: 4507) announced a definitive agreement to acquire IntraBio, a biopharmaceutical company focused on developing and commercializing therapies for neurodegenerative diseases, for an upfront cash consideration…

Foghorn Therapeutics and Lilly Discontinue FHD‑909 and SMARCA2 Programs – Gene Traffic Control Collaboration Ends After Phase 1 Review

Foghorn Therapeutics and Lilly Discontinue FHD‑909 and SMARCA2 Programs – Gene Traffic Control Collaboration Ends After Phase 1 Review

Defand Therapeutics Enters Research Collaboration with Roche – Novel Molecular Glue Degrader Platform Targets Oncology and Immunology

Defand Therapeutics Enters Research Collaboration with Roche – Novel Molecular Glue Degrader Platform Targets Oncology and Immunology

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Asieris Pharmaceuticals Inks Exclusive CEVIRA® License with Theramex – First‑in‑Class Cervical Photodynamic Therapy Enters European Commercialization
CompanyDeals

Asieris Pharmaceuticals Inks Exclusive CEVIRA® License with Theramex – First‑in‑Class Cervical Photodynamic Therapy Enters European Commercialization